Sagimet's second FASN inhibitor TVB-3567 gets IND clearance for acne

Sagimet Biosciences Inc.

FDA's Division of Dermatology and Dentistry cleared IND for TVB-3567, a small molecule FASN inhibitor.
TVB-3567 targets sebum production; FASN drives ~80% of sebum lipids in acne pathogenesis.
First-in-human Phase 1 trial planned for 2025, randomized, double-blind, placebo-controlled.
Building on denifanstat data, partner Ascletis showed significant lesion reduction in Phase 2 acne trial.
Over 50 million acne patients in the US; FASN inhibition seen as significant commercial opportunity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.